Uveal Melanoma: Understanding This Rare Eye Cancer and Its Impact on Vision

Introduction: Unveiling Uveal Melanoma

Uveal melanoma, often simply referred to as ocular melanoma, is a rare but serious form of cancer that originates in the uvea, the middle layer of the eye wall. This layer consists of the iris (the colored part of the eye), the ciliary body (which produces fluid and helps focus the lens), and the choroid (a layer of blood vessels that nourishes the retina). While melanoma is most commonly associated with skin cancer, uveal melanoma is distinct, arising from the pigment-producing cells (melanocytes) found within the eye. Despite its rarity, it is the most common primary intraocular malignancy in adults, affecting approximately 5 to 6 people per million annually in the United States and Europe.

Understanding uveal melanoma is crucial because, unlike skin melanoma, it is not directly linked to sun exposure in the same way, and its symptoms can often be subtle or absent in its early stages. This makes early detection challenging but incredibly important for successful treatment and preservation of vision. This comprehensive guide will delve into the intricacies of uveal melanoma, covering its symptoms, potential causes and risk factors, diagnostic methods, available treatment options, preventive measures, and when it’s critical to seek medical attention.

Symptoms: The Silent Signals of Uveal Melanoma

One of the most challenging aspects of uveal melanoma is its tendency to be asymptomatic in its early stages. Many patients are diagnosed incidentally during routine eye examinations. When symptoms do appear, they often depend on the size and location of the tumor within the uvea.

Commonly Reported Symptoms Include:

• Blurred Vision: This is perhaps the most frequent symptom, especially if the tumor grows in or near the macula, the central part of the retina responsible for sharp, detailed vision.
• Floaters or Flashing Lights: Patients may notice new or increased floaters (small specks or strands that drift across the field of vision) or flashes of light. These occur if the tumor causes a retinal detachment or vitreous hemorrhage.
• Change in Pupil Shape or Size: If the tumor involves the iris, it might cause a noticeable change in the shape of the pupil or how it reacts to light.
• Dark Spot on the Iris: A new or growing dark spot on the iris can be a sign of melanoma in the anterior part of the uvea.
• Pain or Redness: While rare, pain or redness can occur if the tumor grows large enough to cause elevated pressure within the eye (secondary glaucoma) or inflammation.
• Loss of Peripheral Vision: Larger tumors, particularly those in the choroid, can affect the peripheral retina, leading to blind spots or a reduction in the field of vision.

It's important to remember that many of these symptoms can also be caused by less serious eye conditions. However, any new, persistent, or worsening visual changes warrant an immediate consultation with an eye care professional.

Causes and Risk Factors: Who is at Risk?

The exact cause of uveal melanoma is not fully understood, but research has identified several risk factors that increase an individual's likelihood of developing the condition.

Key Risk Factors Include:

• Light Eye Color: Individuals with blue, green, or gray eyes have a higher risk compared to those with brown eyes. This suggests a role for melanin production in susceptibility.
• Fair Skin: Similar to skin melanoma, people with fair skin that burns easily, freckles, and light hair color are at an increased risk.
• Certain Inherited Conditions:
• Oculodermal Melanocytosis (Nevus of Ota): A condition characterized by increased pigmentation around the eye and on the skin.
• Dysplastic Nevus Syndrome: A genetic condition that predisposes individuals to develop multiple atypical moles, increasing the risk of both skin and ocular melanoma.
• BAP1 Tumor Predisposition Syndrome: A rare inherited condition linked to an increased risk of uveal melanoma, mesothelioma, kidney cancer, and other malignancies.
• Age: Uveal melanoma is more common in older adults, with the average age of diagnosis being around 55-60 years.
• Race/Ethnicity: It is significantly more common in Caucasians than in individuals of African or Asian descent.
• Presence of Ocular Melanocytosis or Ocular Nevi: These are benign pigmented lesions within the eye, similar to moles on the skin. While most ocular nevi never turn cancerous, some can transform into melanoma over time. Regular monitoring by an ophthalmologist is crucial for individuals with these lesions.

Unlike skin melanoma, the link between UV radiation exposure and uveal melanoma is less clear and consistently proven. While some studies suggest a possible correlation, it is not as strong or direct as it is for skin cancer. Therefore, traditional sun protection measures for the skin may not offer the same direct protection for the eyes against this specific cancer, though wearing UV-protective sunglasses is always recommended for overall eye health.

Diagnosis: Uncovering Uveal Melanoma

Diagnosing uveal melanoma requires a thorough eye examination and specialized imaging techniques. Early detection is paramount for effective treatment and better outcomes.

The Diagnostic Process Typically Involves:

1. Comprehensive Eye Examination: An ophthalmologist will perform a dilated eye exam, using an ophthalmoscope to visualize the back of the eye (fundus). They will look for any abnormal pigmented lesions, their size, location, and any associated features like fluid under the retina.
2. Ocular Ultrasound (B-scan ultrasonography): This is a crucial diagnostic tool. Sound waves are used to create detailed images of the eye's internal structures, allowing the doctor to measure the tumor's dimensions, assess its internal characteristics (e.g., reflectivity), and detect any associated retinal detachment. It's particularly useful when the view to the back of the eye is obscured.
3. Fluorescein Angiography: A dye is injected into a vein, and photographs are taken as the dye circulates through the blood vessels of the eye. This can highlight abnormal blood vessel patterns within the tumor.
4. Optical Coherence Tomography (OCT): Provides high-resolution cross-sectional images of the retina and choroid, helping to evaluate the tumor's impact on these structures, especially the macula.
5. Fundus Photography: Taking photographs of the lesion allows for documentation and comparison over time to monitor growth or changes.
6. Biopsy (Fine Needle Aspiration Biopsy - FNAB): While not always necessary for diagnosis, a biopsy may be performed in select cases, especially if the diagnosis is uncertain or if genetic analysis of the tumor is desired to predict metastatic risk. A small sample of tumor cells is extracted using a fine needle.
7. Imaging for Metastasis: If uveal melanoma is diagnosed, doctors will often order imaging tests to check for the spread of cancer (metastasis) to other parts of the body, most commonly the liver. These tests may include:
• Liver Function Tests (LFTs): Blood tests to check the health of the liver.
• Abdominal Ultrasound, CT scan, or MRI: To image the liver and detect any suspicious lesions.
• PET Scan: May be used in some cases to detect cancer spread throughout the body.

A definitive diagnosis is usually made based on the characteristic appearance of the lesion during the eye exam and confirmed by ocular ultrasound findings. The combination of these techniques helps differentiate uveal melanoma from other benign pigmented lesions or other eye conditions.

Treatment Options: Tailoring the Approach

The treatment of uveal melanoma is highly individualized, depending on the tumor's size, location, whether it has spread, the patient's overall health, and their visual prognosis. The primary goals of treatment are to eradicate the cancer, preserve vision whenever possible, and prevent metastasis.

Main Treatment Modalities Include:

1. Radiation Therapy

• Brachytherapy (Plaque Radiotherapy): This is one of the most common treatments for small to medium-sized tumors. A small, radioactive plaque (often containing Iodine-125, Palladium-103, or Ruthenium-106) is surgically sewn onto the outer surface of the eye, directly over the tumor. It delivers a high dose of radiation locally to the tumor while minimizing exposure to surrounding healthy tissues. The plaque remains in place for several days and is then surgically removed.
• External Beam Radiation Therapy (EBRT):
• Proton Beam Therapy: A highly precise form of radiation that uses protons to target the tumor with minimal damage to nearby healthy tissue. It is often used for larger tumors or those in challenging locations.
• Stereotactic Radiosurgery (e.g., Gamma Knife, CyberKnife): Delivers highly focused, high-dose radiation beams to the tumor in one or a few treatment sessions. It's often used for smaller tumors or for treating recurrent tumors.

2. Surgical Procedures

• Enucleation: This involves the surgical removal of the entire eye. It is typically reserved for very large tumors, tumors that have caused significant vision loss, or when other treatments are not feasible or have failed. After enucleation, an orbital implant is placed, and a prosthetic eye (shell) is fitted, which can be custom-painted to match the remaining eye.
• Local Resection (Iridectomy, Iridocyclectomy, Choroidectomy): For very small tumors, particularly those in the iris or ciliary body, a portion of the eye containing the tumor may be surgically removed while preserving the rest of the eye. This is less common for posterior uveal melanomas due to the complexity and risk to vision.

3. Laser Therapy

• Transpupillary Thermotherapy (TTT): Uses a low-power infrared laser to heat and destroy small tumors. It is typically effective only for very small, thin melanomas and is sometimes used in combination with radiation therapy.
• Photocoagulation: Uses a laser to burn and destroy tumor cells, usually reserved for very small, anterior lesions.

4. Systemic Therapies (for Metastatic Disease)

Unfortunately, approximately half of all patients with uveal melanoma will develop metastatic disease, most commonly affecting the liver. Treatment options for metastatic uveal melanoma are evolving but remain challenging.

• Chemotherapy: Traditional chemotherapy has shown limited effectiveness against metastatic uveal melanoma.
• Immunotherapy: Drugs that boost the body's immune system to fight cancer, such as checkpoint inhibitors (e.g., nivolumab, pembrolizumab), are being investigated and used in some cases of metastatic uveal melanoma, often with varying success. Tebentafusp-tebn (Kimmtrak) is a novel bispecific fusion protein that has shown improved overall survival in patients with metastatic uveal melanoma who are HLA-A*02:01 positive.
• Targeted Therapy: Drugs that specifically target molecular pathways involved in cancer growth are under investigation.
• Liver-Directed Therapies: Since the liver is the most common site of metastasis, treatments like hepatic arterial chemoembolization, radioembolization, or isolated hepatic perfusion may be used to deliver high doses of therapy directly to liver tumors.

The choice of treatment is made by a multidisciplinary team of specialists, including ophthalmologists, ocular oncologists, radiation oncologists, and medical oncologists. Patients should discuss all available options, their potential benefits, and risks with their healthcare team.

Prevention: Is Uveal Melanoma Avoidable?

Currently, there are no definitive preventive measures for uveal melanoma because its primary causes are not fully understood or directly linked to controllable environmental factors like UV exposure in the same way as skin melanoma.

However, certain practices are recommended:

• Regular Comprehensive Eye Exams: This is the most crucial